Immusoft is at the forefront of utilizing B cells as biofactories for the delivery of therapeutic proteins through its innovative approach known as Immune System Programming (ISP™). This technology involves collecting a patient's B cells, which can be stimulated to transform into plasma cells—highly efficient producers of antibodies. By programming these B cells to produce specific therapeutic proteins, Immusoft expands and differentiates them into plasma cells that can generate large quantities of the desired proteins. Once infused back into the patient, these programmed cells are expected to reside in the body long-term, providing sustained therapeutic benefits.

The ISP™ approach offers several advantages over traditional gene therapy methods, such as viral delivery systems and stem cell modifications. Unlike viral therapies, which can only be administered once and may not adapt to a patient's changing needs, Immusoft's non-viral method allows for potential re-dosing without the need for myeloablation, a toxic procedure often required in stem cell therapies. Additionally, ISP™ aims to improve upon enzyme replacement therapies, which typically require frequent and lengthy infusions. By leveraging the natural capabilities of B cells, Immusoft envisions a more efficient and patient-friendly method for delivering a wide range of therapeutic proteins, including enzymes, antibodies, and signaling proteins, thereby enhancing treatment options for various conditions.

United States

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

Immusoft

Company Details